Nobel Biocare Stock Price, News & Analysis (OTCMKTS:NBHGF)

$18.25 0.00 (0.00 %)
(As of 12/15/2017 05:15 AM ET)
Previous Close$18.25
Today's Range$18.25 - $18.25
52-Week Range$16.35 - $19.50
Average VolumeN/A
Market Capitalization$2.26 billion
P/E RatioN/A
Dividend YieldN/A

About Nobel Biocare (OTCMKTS:NBHGF)

Receive NBHGF News and Ratings via Email

Sign-up to receive the latest news and ratings for NBHGF and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A


Outstanding Shares123,780,000

Nobel Biocare (OTCMKTS:NBHGF) Frequently Asked Questions

What is Nobel Biocare's stock symbol?

Nobel Biocare trades on the OTCMKTS under the ticker symbol "NBHGF."

How were Nobel Biocare's earnings last quarter?

Nobel Biocare Ag (OTCMKTS:NBHGF) released its quarterly earnings results on Thursday, August, 21st. The company reported $0.17 EPS for the quarter, topping analysts' consensus estimates of $0.12 by $0.05. The company had revenue of $191.67 million for the quarter, compared to the consensus estimate of $171.79 million. View Nobel Biocare's Earnings History.

Who are some of Nobel Biocare's key competitors?

How do I buy Nobel Biocare stock?

Shares of Nobel Biocare can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Nobel Biocare's stock price today?

One share of Nobel Biocare stock can currently be purchased for approximately $18.25.

How big of a company is Nobel Biocare?

Nobel Biocare has a market capitalization of $2.26 billion.

How can I contact Nobel Biocare?

Nobel Biocare's mailing address is P.O. Box 8058, Zurich Fl, V8. The company can be reached via phone at 41-43-211-4200 or via email at [email protected]

MarketBeat Community Rating for Nobel Biocare (NBHGF)

Community Ranking:  1.8 out of 5 (star)
Outperform Votes:  9 (Vote Outperform)
Underperform Votes:  16 (Vote Underperform)
Total Votes:  25
MarketBeat's community ratings are surveys of what our community members think about Nobel Biocare and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Nobel Biocare (OTCMKTS:NBHGF) Analyst Ratings History

No equities research coverage for this company has been tracked by MarketBeat


Nobel Biocare (OTCMKTS:NBHGF) Earnings History and Estimates Chart

Earnings by Quarter for Nobel Biocare (OTCMKTS:NBHGF)

Nobel Biocare (OTCMKTS NBHGF) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/21/2014Q2 2014$0.12$0.17$171.79 million$191.67 millionViewN/AView Earnings Details
4/29/2014Q1 2014$0.15$0.14$178.32 million$190.27 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Nobel Biocare (OTCMKTS:NBHGF) Earnings Estimates

No earnings estimates for this company have been tracked by


Dividend History for Nobel Biocare (OTCMKTS:NBHGF)

No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Nobel Biocare (OTCMKTS NBHGF)

No insider trades for this company have been tracked by


Nobel Biocare (OTCMKTS NBHGF) News Headlines


SEC Filings

Nobel Biocare (OTCMKTS:NBHGF) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Financials are not available for this stock.


Nobel Biocare (OTCMKTS NBHGF) Stock Chart for Friday, December, 15, 2017

Loading chart…

This page was last updated on 12/15/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.